– Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, et al. Mutational landscape and significance across 12 major cancer types. Nature. 2013;502:333–9.
– Papadia A, Imboden S, Siegenthaler F, Gasparri ML, Mohr S, Lanz S, Mueller MD. Laparoscopic Indocyanine Green Sentinel Lymph Node Mapping in Endometrial Cancer.Ann Surg Oncol. 2016;23(7):2206–11.
– Halaska M J, Haidopoulos D, Guyon F. European Society of Gynecological Oncology Statement on Fibroid and Uterine Morcellation. Int J Gynecol Cancer. 2017;27:189–192.
– Ramirez PT, Frumovitz M, Pareja R, Lopez A, Vieira M, Ribeiro R, et al. Minimally invasive versus abdominal radical hysterectomy for cervical cancer.N Engl J Med. 2018;379:1895–904.
1 Heusser R, Baumann A, Noseda G. Krebs in der Schweiz: wichtige Zahlen. Krebsliga Schweiz. 2017;23:588–96.
doi:10.1007/s00761-017-0252-4
2 Kandoth C, McLellan MD, Vandin F, et al. Mutational landscape and significance across 12 major cancer types. Nature. 2013;502:333–9.
doi:10.1038/nature12634
3 Colombo N, Creutzberg C, Amant F, et al. ESMO-ESGO-ESTRO consensus conference on endometrial cancer: Diagnosis, treatment and follow-up. Ann Oncol. 2016;27:16–41.
doi:10.1093/annonc/mdv484
4 Emons G, Steiner E. S3-Leitlinie Diagnostik, Therapie und Nachsorge der Patientinnen mit EndometriumkarzinomS3 guideline diagnosis, treatment, and aftercare of endometrial cancer patients. Gynakologe. 2018;51:996–9.
doi:10.1007/s00129-018-4333-2
5 Papadia A, Imboden S, Siegenthaler F, et al. Laparoscopic Indocyanine Green Sentinel Lymph Node Mapping in Endometrial Cancer. Ann Surg Oncol. 2016;23. doi:10.1245/s10434-016-5090-x
6 Imboden S, Mereu L, Siegenthaler F, et al. Oncological safety and perioperative morbidity in low-risk endometrial cancer with sentinel lymph-node dissection. Eur J Surg Oncol. 2019;45:1638–43.
doi:10.1016/j.ejso.2019.05.026
7 Rossi EC, Kowalski LD, Scalici J, et al. A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): a multicentre, prospective, cohort study. Lancet Oncol. 2017;18:384–92.
doi:10.1016/S1470-2045(17)30068-2
8 Nirgianakis K, Novak U, Mueller M. Interdisziplinäre Behandlung des Endometriumkarzinoms. Swiss Med Forum. 2015;15:1050–4.
doi:10.4414/smf.2015.02455
9 de Boer SM, Powell ME, Mileshkin L, et al. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. Lancet Oncol. 2019;20:1273–85.
doi:10.1016/S1470-2045(19)30395-X
10 Matei D, Filiaci V, Randall ME, et al. Adjuvant chemotherapy plus radiation for locally advanced endometrial cancer. N Engl J Med. 2019;380:2317–26.
doi:10.1056/NEJMoa1813181
11 Ott PA, Bang YJ, Berton-Rigaud D, et al. Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results from the KEYNOTE-028 Study. Obstet Gynecol Surv. 2018;73:26–7.
doi:10.1097/01.ogx.0000527579.58363.20
12 Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509–20.
doi:10.1056/NEJMoa1500596
13 Makker V, Rasco D, Vogelzang NJ, et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol 2019;20:711–8.
doi:10.1016/S1470-2045(19)30020-8
14 Benson C, Miah AB. Uterine sarcoma – Current perspectives. Int J Womens Health. 2017;9:597–606.
doi:10.2147/IJWH.S117754
15 Santos P, Cunha TM. Uterine sarcomas: Clinical presentation and MRI features. Diagnostic Interv Radiol. 2015;21:4–9.
doi:10.5152/dir.2014.14053
16 Halaska MJ, Haidopoulos D, Fre Þ, et al. European Society of Gynecological Oncology Statement on Fibroid and Uterine Morcellation. Int J Gynecol Cancer. 2017;27:189–92.
doi:10.1097/IGC.0000000000000911
17 Sarkome U, Inzidenz D, Tumortypisierung D, et al. S2k-Leitlinie: Uterine Sarkome. 2017;400–5.
18 Hensley ML, Wathen JK, Maki RG, et al. Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: Results of a phase 2 trial (SARC 005). Cancer .2013;119:1555–61.
doi:10.1002/cncr.27942
19 Tirri BF, Petignat P, Jaccot-guillarmod M, et al. Empfehlungen für die Gebärmutterhalskrebsvorsorge. Schweizerische Gesellschaft für Gynäkologie und Geburtshilfe. Expertenbrief No 50. 2012.
20 S3-Leitlinie Zervixkarzinom. Leitlinienprogramm Onkologie, S3-Leitlinie Prävention des Zervixkarzinoms Langversion 1.0. 2017;1–239.
21 AWMF. S3-Leitlinie Diagnostik , Therapie und Nachsorge der Patientin mit Zervixkarzinom. Awmf. 2014;:1–74.
22 Bhatla N, Berek JS, Cuello Fredes M, et al. Revised FIGO staging for carcinoma of the cervix uteri. Int J Gynecol Obstet. 2019;145:129–35.
doi:10.1002/ijgo.12749
23 Cibula D, Pötter R, Planchamp F, et al. The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients With Cervical Cancer. Int J Gynecol Cancer.2018;28:641–55.
doi:10.1097/IGC.0000000000001216
24 Koh WJ, Abu-Rustum NR, Bean S, et al. Cervical cancer, version 3.2019. JNCCN J Natl Compr Cancer Netw. 2019;17:64–84.
doi:10.6004/jnccn.2019.0001
25 Ramirez PT, Frumovitz M, Pareja R, et al. Minimally invasive versus abdominal radical hysterectomy for cervical cancer. N Engl J Med .2018;379:1895–904.
doi:10.1056/NEJMoa1806395
26 Chung HC, Ros W, Delord J, et al. Ef fi cacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study abstract. 2020;37.